A patient with a partial rotator cuff tear or moderate hip OA arrives at your site after reading FDA enforcement letters and Reddit threads. They want to know what a same-day BMAC procedure actually is, why some clinics advertise $20,000 stem cell packages and some quote $2,400, whether the FDA considers BMAC and lipoaspirate to be same-day minimally manipulated autologous products, and what the realistic outcome is for a 60-year-old with a non-retracted supraspinatus tear. The honest clinics lose calls every day to clinics with louder marketing.

SleekAI maps your orthobiologic catalog (BMAC from posterior superior iliac spine, micro-fragmented adipose tissue, hyaluronic acid combination protocols), evidence summaries, candidacy rules, and the products you do not offer (cultured stem cell products from third-party labs, amniotic or fetal-derived injections marketed as live stem cells, exosome products marketed for orthopedic indications). Pull cash_price, evidence_level, typical_response_rate, aspirate_site, and fda_status from postmeta on your therapy posts. The bot tells a visitor that BMAC at your clinic is $2,400, drawn from the posterior superior iliac spine under local with light sedation, that response rates for partial rotator cuff tears run 60 to 75%, and that the procedure is performed by a board-certified physician.

Generic bots either overpromise stem cell results or refuse to engage at all because of the term. Patients deserve better. SleekAI lets honest clinics explain BMAC and adipose treatments accurately, name the FDA's same-day autologous minimal manipulation framework, and decline products like cultured cells or amniotic injections that fall outside that framework. The transparency converts skeptical patients into trusting ones.

Stem cell therapy is one of the most distorted markets in medicine. FDA enforcement against clinics selling unapproved cultured products has been ongoing since 2017, and patients arrive at honest clinics already skeptical. The clinics that survive and thrive are the ones whose marketing matches their procedure: same-day autologous, minimally manipulated, transparently priced.

A bot that explains that distinction plainly, on the first visit, builds trust faster than any landing page. The bot is also a candidacy gate. Many patients who think they want stem cells are actually surgical candidates or have pathology that does not respond to orthobiologics.

A bot that screens them upfront and routes them to a surgical or referring consult saves the patient money and saves the clinic from delivering a treatment that will not help. The transcripts are a content goldmine. They show which competitor packages patients have been pitched, which products they have heard about, and which evidence questions they actually have.

That data trains your front desk and tightens your content. Honest stem cell clinics are an underserved market because the loud predatory clinics dominate the search results. A chatbot that demonstrates ethical practice in the first 30 seconds of a visit shifts that balance.

The clinics that win the next decade will be the ones whose first conversation already feels like an honest medical conversation. A working chatbot is the fastest way to get there.